← Patent-cliff monitor small molecule TASIGNA NILOTINIB HYDROCHLORIDE
Loss of exclusivity October 2032 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name TASIGNA Active ingredient NILOTINIB HYDROCHLORIDE Strength EQ 150MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval June 2010 Marketing status RX
Listed patents Patent Expires Type 9061029*PED October 2032 — 9061029 April 2032 substance 8163904*PED February 2029 — 8163904 August 2028 substance, product 8293756*PED March 2028 — 8293756 September 2027 product 8501760*PED January 2027 — 8389537*PED January 2027 — 8415363*PED January 2027 — 8415363 July 2026 substance, product 8389537 July 2026 use U-1374 8501760 July 2026 product
Regulatory exclusivity Code Expires PED March 2029 ODE-380 September 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.